PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that reduced loading dose of prasugrel followed by reduced
maintenance dose of prasugrel in acute coronary syndrome patients with CYP2C19 polymorphism
undergoing percutaneous coronary intervention might exhibit lower platelet reactivity 24
hours and 30 days later which is associated with major adverse cardiovascular events.